IPO Databook: Iambic Therapeutics (IAM US) - Oct 2026

93 Views10 Oct 2026 11:30

SUMMARY

Iambic Therapeutics, Inc. is a technology and clinical-stage life sciences company integrating proprietary AI with automated experimentation to transform the biopharmaceutical industry.
The company's most advanced program, IAM1363, is in a Phase 1/1b clinical trial as of September 2026, with a registrational trial anticipated as early as 2027.
The company reported collaboration revenue of $12,753 thousand for the six months ended June 30, 2026, alongside a net loss of $(50,116) thousand for the same period.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream